Case Study: A 74-years male with Bronchogenic carcinoma (SCC)
Background: Bronchogenic Carcinoma is expected to account for approximately 95% of all primary lung cancers. This type of carcinoma arises from respiratory epithelium cells and represents malignant neoplasm. Generally, Bronchogenic Carcinoma involves two basic histological types: small cell carcinoma, and non-small cell carcinomas (i.e. large cell carcinoma, squamous cell carcinoma, and adenocarcinoma)
Clinical History: A know case of Bronchogenic carcinoma, a baseline FDG PET/CT study (on July 21, 2019) showed abnormal results with “Stage IV” of the disease. Status post 10 fractions of radiation (ended on Oct 8, 2019) and 04 cycles of chemo (last received Sep 27, 2019), second FDG PET/CT (October 16, 2019) showed the disease was metabolically Progressive. The patient was still on oral chemo (after completing 7 cycles, last received on Jan 18, 2020) when this follow up FDG PET/CT was carried out (Feb 2, 2020).
Our Findings: This is an abnormal follow up FDG PET/CT study.
· Interval progression in numbers and sizes of multiple hypermetabolic bilateral lung nodules with largest lesion in upper lobe of left lung.
· Redemonstration of hypermetabolic left cervical and mediastinal nodes with appearance of new nodes.
· Interval appearance of hypermetabolic retroperitoneal nodes.
· Interval appearance of hypermetabolic and hypodense liver deposits.
· Interval progression in hypermetabolic mixed sclerotic bony metastases with appearance of new deposits.
· Metabolically Progressive Disease.
